Lupin launches Flucytosine capsules in US market

PTI New Delhi | Updated on January 08, 2018

Lupin has launched Flucytosine capsules, used to treat serious infections, in the American market. The company has launched its generic product in the strengths of 250 mg and 500 mg after having received approval from the US Food and Drug Administration (USFDA), Lupin said in a regulatory filing.

The Mumbai-based company’s product is the generic version of Valeant Pharmaceuticals International Inc’s Ancobon tablets.The drug is indicated for the treatment of serious infections. As per the latest IMS sales data, Flucytosine capsules have annual sales of around $48 million in the US.

Lupin shares ended up by 2.38 per cent Rs 898.40 on the BSE.

Published on January 05, 2018

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like